Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
NCT07038252

The Effect of Oral SPM Supplementation on INflammation-induced Vascular Ageing in Obese Hypertensive Patients

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-04-17

60

Participants Needed

1

Research Sites

65 weeks

Total Duration

On this page

Sponsors

A

Assistance Publique - Hôpitaux de Paris

Lead Sponsor

N

National Research Agency, France

Collaborating Sponsor

AI-Summary

What this Trial Is About

Cardiovascular risk factors such as obesity, diabetes, high blood pressure, high cholesterol, or smoking are associated with an increased risk of events such as myocardial infarction, stroke, or peripheral artery disease. Lifestyle and dietary measures, as well as pharmacological treatments, can help correct these risk factors. However, several studies have shown that even with optimal treatment, individuals at high risk still face a residual cardiovascular risk. This phenomenon is primarily attributed to the development of vascular lesions, meaning damage within the blood vessels. These lesions are largely due to inflammation, an activated immune state that is more pronounced in overweight individuals and significantly contributes to vascular damage, potentially shortening the lifespan of those with cardiovascular disease. Although anti-inflammatory therapies have proven effective in reducing this risk, they may interfere with tissue repair and the immune system. For this reason, it is essential to identify strategies that promote the resolution of inflammation without compromising these vital processes. Specialized pro-resolving mediators (SPMs) are compounds derived from omega-3 and omega-6 polyunsaturated fatty acids, which are naturally found in various foods such as fish. These mediators help limit the infiltration of inflammatory cells and initiate the repair of damaged tissues. This type of dietary supplement is already available over the counter, but its health benefits have not been extensively studied. Experimental animal studies have shown that restoring inflammation resolution through SPMs can prevent-or even reverse-cardiovascular damage and inflammation by directly acting on vascular cells and modulating the immune system. However, human data on the role of SPMs and inflammation resolution in vascular disease remain very limited. The investigators hypothesize that in individuals at high cardiovascular risk (due to obesity and hypertension), increasing circulating levels of SPMs through oral supplementation (as a dietary supplement) would improve vascular function, metabolic profile, and inflammatory and immune cell responses. In doing so, this may help reduce the residual risk of cardiovascular disease. The objective of this research is to assess whether a supplement enriched with SPMs can facilitate the resolution of inflammation, which is essential for restoring vascular function and thereby supporting the body's natural tissue repair mechanisms. To address the research question, the study plans to include 60 individuals with obesity and hypertension, all presenting a high cardiovascular risk, recruited from healthcare facilities located in France. This research is publicly funded by the French National Research Agency (Agence Nationale de la Recherche) through the European research project RESPIN-VAR, co-funded by ERA4Health and the European Union.

CONDITIONS

Official Title

The Effect of Oral SPM Supplementation on INflammation-induced Vascular Ageing in Obese Hypertensive Patients

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 85 years
  • Hypertension controlled under pharmacological or non-pharmacological treatment with office blood pressure below 140/90 mmHg at inclusion
  • Body mass index (BMI) greater than 30 kg/m²
  • Stable antihypertensive treatment for at least one month before inclusion
  • Signed informed consent
  • Affiliated with social security
Not Eligible

You will not qualify if you...

  • Secondary hypertension based on medical history
  • Stroke within the previous 6 months
  • Myocardial infarction within the previous 6 months
  • Severe liver failure
  • Chronic kidney disease with estimated glomerular filtration rate below 30 ml/min/1.73 m²
  • Pregnancy or breastfeeding
  • Regular use of nitric oxide donors or phosphodiesterase inhibitors
  • Inability to comply with study protocol
  • Under legal protection and unable to give informed consent
  • Receiving state medical aid (AME)
  • Participation in another interventional study
  • Allergy to ultrasound gel
  • Allergy or hypersensitivity to omega-3 acids, fish, or soy
  • Chronic inflammatory diseases
  • Use of chronic anti-inflammatory treatment within one month before inclusion
  • Use of omega-3 or omega-6 supplements within one month before inclusion
  • Life expectancy less than one year

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Service de Pharmacologie - UF Pharmacologie Clinique

Paris, France

Actively Recruiting

Loading map...

Research Team

T

Tiffany MARTIN

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

The Effect of Oral SPM Supplementation on INflammation-induced Vascular Ageing in Obese Hypertensive Patients | DecenTrialz